Global Prostate Cancer Antigen 3 Test Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Prostate Cancer Antigen 3 Test market size will reach 66.72 Million USD in 2025 and is projected to reach 123.70 Million USD by 2032, with a CAGR of 9.22% (2025-2032). Notably, the China Prostate Cancer Antigen 3 Test market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
The Prostate Cancer Antigen 3 (PCA3) test is a diagnostic test used to help detect prostate cancer, particularly in men with elevated prostate-specific antigen (PSA) levels or abnormal digital rectal examination (DRE) results. Unlike the PSA test, which measures the levels of a protein produced by both normal and cancerous prostate cells, the PCA3 test specifically measures the levels of PCA3 RNA, a non-coding RNA molecule that is overexpressed in prostate cancer cells. The PCA3 test is typically performed on a urine sample collected after a digital rectal examination (DRE). Higher levels of PCA3 RNA in the urine sample may indicate the presence of prostate cancer. The PCA3 test is often used in conjunction with other diagnostic tests, such as PSA testing and prostate biopsy, to help assess the risk of prostate cancer and guide treatment decisions. While the PCA3 test can provide valuable information, it is not a standalone test for diagnosing prostate cancer and should be interpreted in conjunction with other clinical findings.
The major global suppliers of Prostate Cancer Antigen 3 Test include MDxHealth, Myriad Genetics, Inc, Abbott, F. Hoffmann-La Roche Ltd, Siemens, OPKO Health, Inc, Genomic Health, BD, Agilent Technologies, Inc, Danaher, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Prostate Cancer Antigen 3 Test. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Prostate Cancer Antigen 3 Test market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Prostate Cancer Antigen 3 Test market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Prostate Cancer Antigen 3 Test industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Prostate Cancer Antigen 3 Test Include:
MDxHealth
Myriad Genetics, Inc
Abbott
F. Hoffmann-La Roche Ltd
Siemens
OPKO Health, Inc
Genomic Health
BD
Agilent Technologies, Inc
Danaher
Prostate Cancer Antigen 3 Test Product Segment Include:
RT-PCR
ELISA Test
Micro-neutralization Assays
Prostate Cancer Antigen 3 Test Product Application Include:
Hospital
Specialist Clinic
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Prostate Cancer Antigen 3 Test Industry PESTEL Analysis
Chapter 3: Global Prostate Cancer Antigen 3 Test Industry Porter's Five Forces Analysis
Chapter 4: Global Prostate Cancer Antigen 3 Test Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Prostate Cancer Antigen 3 Test Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Prostate Cancer Antigen 3 Test Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Prostate Cancer Antigen 3 Test Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Prostate Cancer Antigen 3 Test market size will reach 66.72 Million USD in 2025 and is projected to reach 123.70 Million USD by 2032, with a CAGR of 9.22% (2025-2032). Notably, the China Prostate Cancer Antigen 3 Test market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
The Prostate Cancer Antigen 3 (PCA3) test is a diagnostic test used to help detect prostate cancer, particularly in men with elevated prostate-specific antigen (PSA) levels or abnormal digital rectal examination (DRE) results. Unlike the PSA test, which measures the levels of a protein produced by both normal and cancerous prostate cells, the PCA3 test specifically measures the levels of PCA3 RNA, a non-coding RNA molecule that is overexpressed in prostate cancer cells. The PCA3 test is typically performed on a urine sample collected after a digital rectal examination (DRE). Higher levels of PCA3 RNA in the urine sample may indicate the presence of prostate cancer. The PCA3 test is often used in conjunction with other diagnostic tests, such as PSA testing and prostate biopsy, to help assess the risk of prostate cancer and guide treatment decisions. While the PCA3 test can provide valuable information, it is not a standalone test for diagnosing prostate cancer and should be interpreted in conjunction with other clinical findings.
The major global suppliers of Prostate Cancer Antigen 3 Test include MDxHealth, Myriad Genetics, Inc, Abbott, F. Hoffmann-La Roche Ltd, Siemens, OPKO Health, Inc, Genomic Health, BD, Agilent Technologies, Inc, Danaher, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Prostate Cancer Antigen 3 Test. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Prostate Cancer Antigen 3 Test market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Prostate Cancer Antigen 3 Test market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Prostate Cancer Antigen 3 Test industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Prostate Cancer Antigen 3 Test Include:
MDxHealth
Myriad Genetics, Inc
Abbott
F. Hoffmann-La Roche Ltd
Siemens
OPKO Health, Inc
Genomic Health
BD
Agilent Technologies, Inc
Danaher
Prostate Cancer Antigen 3 Test Product Segment Include:
RT-PCR
ELISA Test
Micro-neutralization Assays
Prostate Cancer Antigen 3 Test Product Application Include:
Hospital
Specialist Clinic
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Prostate Cancer Antigen 3 Test Industry PESTEL Analysis
Chapter 3: Global Prostate Cancer Antigen 3 Test Industry Porter's Five Forces Analysis
Chapter 4: Global Prostate Cancer Antigen 3 Test Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Prostate Cancer Antigen 3 Test Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Prostate Cancer Antigen 3 Test Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Prostate Cancer Antigen 3 Test Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Prostate Cancer Antigen 3 Test Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Prostate Cancer Antigen 3 Test Product by Type
- 1.2.1 RT-PCR
- 1.2.2 ELISA Test
- 1.2.3 Micro-neutralization Assays
- 1.3 Prostate Cancer Antigen 3 Test Product by Application
- 1.3.1 Hospital
- 1.3.2 Specialist Clinic
- 1.3.3 Other
- 1.4 Global Prostate Cancer Antigen 3 Test Market Size Analysis (2020-2032)
- 1.5 Prostate Cancer Antigen 3 Test Market Development Status and Trends
- 1.5.1 Prostate Cancer Antigen 3 Test Industry Development Status Analysis
- 1.5.2 Prostate Cancer Antigen 3 Test Industry Development Trends Analysis
- 2 Prostate Cancer Antigen 3 Test Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Prostate Cancer Antigen 3 Test Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Prostate Cancer Antigen 3 Test Market Analysis by Country
- 4.1 Global Prostate Cancer Antigen 3 Test Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Prostate Cancer Antigen 3 Test Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Prostate Cancer Antigen 3 Test Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.5 China Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.6 France Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.14 India Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Prostate Cancer Antigen 3 Test Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Prostate Cancer Antigen 3 Test Market Revenue by Key Suppliers (2021-2025)
- 5.2 Prostate Cancer Antigen 3 Test Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Prostate Cancer Antigen 3 Test Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Prostate Cancer Antigen 3 Test Market Analysis by Type
- 6.1 Global Prostate Cancer Antigen 3 Test Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Prostate Cancer Antigen 3 Test Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 MDxHealth
- 7.1.1 MDxHealth Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 MDxHealth Prostate Cancer Antigen 3 Test Product Portfolio
- 7.1.3 MDxHealth Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Myriad Genetics, Inc
- 7.2.1 Myriad Genetics, Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Myriad Genetics, Inc Prostate Cancer Antigen 3 Test Product Portfolio
- 7.2.3 Myriad Genetics, Inc Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Abbott
- 7.3.1 Abbott Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Abbott Prostate Cancer Antigen 3 Test Product Portfolio
- 7.3.3 Abbott Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 F. Hoffmann-La Roche Ltd
- 7.4.1 F. Hoffmann-La Roche Ltd Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 F. Hoffmann-La Roche Ltd Prostate Cancer Antigen 3 Test Product Portfolio
- 7.4.3 F. Hoffmann-La Roche Ltd Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Siemens
- 7.5.1 Siemens Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Siemens Prostate Cancer Antigen 3 Test Product Portfolio
- 7.5.3 Siemens Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 OPKO Health, Inc
- 7.6.1 OPKO Health, Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 OPKO Health, Inc Prostate Cancer Antigen 3 Test Product Portfolio
- 7.6.3 OPKO Health, Inc Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Genomic Health
- 7.7.1 Genomic Health Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Genomic Health Prostate Cancer Antigen 3 Test Product Portfolio
- 7.7.3 Genomic Health Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 BD
- 7.8.1 BD Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 BD Prostate Cancer Antigen 3 Test Product Portfolio
- 7.8.3 BD Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 Agilent Technologies, Inc
- 7.9.1 Agilent Technologies, Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Agilent Technologies, Inc Prostate Cancer Antigen 3 Test Product Portfolio
- 7.9.3 Agilent Technologies, Inc Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Danaher
- 7.10.1 Danaher Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Danaher Prostate Cancer Antigen 3 Test Product Portfolio
- 7.10.3 Danaher Prostate Cancer Antigen 3 Test Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Prostate Cancer Antigen 3 Test Industry Chain Analysis
- 8.2 Prostate Cancer Antigen 3 Test Product Downstream Application Analysis
- 8.2.1 Global Prostate Cancer Antigen 3 Test Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Prostate Cancer Antigen 3 Test Revenue and Forecast by Application (2020-2032)
- 8.3 Prostate Cancer Antigen 3 Test Typical Downstream Customers
- 8.4 Prostate Cancer Antigen 3 Test Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
